CMC Biologics and IDT Biologika GmbH have entered a strategic collaboration aimed at providing more complete and efficient services for the manufacture of antibody drug conjugates (ADCs).
 
CMC Biologics will perform process development and manufacture of the bulk monoclonal antibody and IDT Biologika will perform services from conjugation of the cytotoxic drug to the antibody substance through to aseptic fill, finish and packaging of the final ADC drug product. This joint manufacturing service aims to provide faster, more reliable, quality ADC manufacturing and a simplified supply chain, from DNA to finished drug product, for clinical trials through commercial manufacturing.
 
“The collaboration with CMC Biologics is an important step to provide full ADC manufacturing services to meet the needs of ADC development and production in this rapidly growing field,” said Dr. Ralf Pfirmann, chief executive officer of IDT Biologika. “Our new collaboration permits IDT Biologika to leverage its biologics and cytotoxics capabilities and facilities, and their unique combination in the business, manufacturing and development portfolio at IDT´s Dessau headquarter site, to provide ADC developers with a highly reliable and efficient solution for early process development through clinical and commercial manufacturing.”
 
“We are delighted to be working with IDT Biologika, one of the fastest growing and innovative CMOs in Germany and now in North America,” said Gustavo Mahler, Ph.D., chief executive officer of CMC Biologics. “We share the common values with IDT Biologika with a constant focus on manufacturing excellence and a dedication to customer service.”